Equities researchers at Jefferies Financial Group started coverage on shares of Acrivon Therapeutics (NASDAQ:ACRV – Get Rating) in a research report issued to clients and investors on Monday, Briefing.com reports. The firm set a “buy” rating and a $17.00 price target on the stock. Jefferies Financial Group’s price objective indicates a potential upside of 35.03% […]